MX2009011416A - Tia(di)azoles como antagonistas del receptor de dopamina 2 de disociacion rapida. - Google Patents

Tia(di)azoles como antagonistas del receptor de dopamina 2 de disociacion rapida.

Info

Publication number
MX2009011416A
MX2009011416A MX2009011416A MX2009011416A MX2009011416A MX 2009011416 A MX2009011416 A MX 2009011416A MX 2009011416 A MX2009011416 A MX 2009011416A MX 2009011416 A MX2009011416 A MX 2009011416A MX 2009011416 A MX2009011416 A MX 2009011416A
Authority
MX
Mexico
Prior art keywords
receptor antagonists
zoles
thia
dia
compounds
Prior art date
Application number
MX2009011416A
Other languages
English (en)
Inventor
Gregor James Macdonald
Jose Manuel Bartolome-Nebreda
Michiel Luc Maria Van Gool
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2009011416A publication Critical patent/MX2009011416A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a [1-(bencil)-piperidin-4-iI]-([1 ,3,4]tiadiazol-2-iI)-amina y derivados de [1-(bencil)-piperidin-4- il]-(tiazol-2-il)-amina de fórmula (I) que son antagonistas del receptor de dopamina 2 de disociación rápida, los procesos para preparar estos compuestos, las composiciones farmacéuticas que comprenden estos compuestos como un ingrediente activo; los compuestos se usan como medicamentos para tratar o prevenir trastornos del sistema nervioso central, por ejemplo esquizofrenia, al ejercer un efecto antipsicótico sin efectos secundarios motores.
MX2009011416A 2007-04-23 2008-04-18 Tia(di)azoles como antagonistas del receptor de dopamina 2 de disociacion rapida. MX2009011416A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07106706 2007-04-23
PCT/EP2008/054732 WO2008128996A1 (en) 2007-04-23 2008-04-18 Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists

Publications (1)

Publication Number Publication Date
MX2009011416A true MX2009011416A (es) 2009-11-05

Family

ID=38476031

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011416A MX2009011416A (es) 2007-04-23 2008-04-18 Tia(di)azoles como antagonistas del receptor de dopamina 2 de disociacion rapida.

Country Status (15)

Country Link
US (1) US8933101B2 (es)
EP (1) EP2148879B1 (es)
JP (1) JP5431306B2 (es)
KR (1) KR101506156B1 (es)
CN (1) CN101663299A (es)
AR (1) AR066242A1 (es)
AU (1) AU2008240729B2 (es)
CA (1) CA2682671C (es)
CL (1) CL2008001158A1 (es)
ES (1) ES2400710T3 (es)
IL (1) IL201661A (es)
MX (1) MX2009011416A (es)
RU (1) RU2489431C2 (es)
TW (1) TWI423969B (es)
WO (1) WO2008128996A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
EP2148872A1 (en) * 2007-04-23 2010-02-03 Janssen Pharmaceutica, N.V. Pyridine derivatives as fast dissociating dopamine 2 receptor antagonists
EP2148873B1 (en) * 2007-04-23 2012-08-29 Janssen Pharmaceutica, N.V. 4-alkoxypyridazine derivatives as fast dissociating dopamine 2 receptor antagonists
WO2010000456A1 (en) * 2008-07-03 2010-01-07 Janssen Pharmaceutica Nv Substituted 6- (1-piperazinyl) -pyridazines as 5-ht6 receptor antagonists
JP5457450B2 (ja) * 2008-07-31 2014-04-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 迅速解離性ドーパミン２受容体拮抗薬としてのピペラジン−１−イル−トリフルオロメチル−置換−ピリジン
AU2016245434B2 (en) * 2015-04-07 2020-10-29 Ela Pharma Ltd Compositions for treating and/or preventing cell or tissue necrosis specifically targeting Cathepsin C and/or CELA1 and/or CELA3A and/or structurally related enzymes thereto

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3933823A (en) * 1971-03-29 1976-01-20 E. R. Squibb & Sons, Inc. Isoxazolopyridine ketone derivatives
DE2341965C3 (de) * 1973-08-20 1979-01-25 C.H. Boehringer Sohn, 6507 Ingelheim 4- [N- (o-PyridyD- N-acyl] -aminolphenäthylpiperidine, Verfahren zu deren Herstellung sowie deren Verwendung bei der Bekämpfung von Schmerzzuständen
US4197304A (en) * 1975-09-23 1980-04-08 Janssen Pharmaceutica N.V. N-Aryl-N-(1-L-4-piperidinyl)-arylacetamides
NO147672C (no) 1975-09-23 1983-05-25 Janssen Pharmaceutica Nv Analogifremgangsmaate for fremstilling av n-aryl-n-(1-l1-4-piperidinyl)-arylacetamider
EG12406A (en) * 1976-08-12 1979-03-31 Janssen Pharmaceutica Nv Process for preparing of novel n-aryl-n-(1-l-4-piperidinyl)-arylacetamides
DE3218482A1 (de) 1982-05-15 1983-11-17 Bayer Ag, 5090 Leverkusen Substituierte 5-trifluormethyl-1,3,4-thiadiazol-2-yloxyessigsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als herbizide
ES8802151A1 (es) 1985-07-31 1988-04-01 Janssen Pharmaceutica Nv Un procedimiento para la preparacion de nuevos piridazinaminas.
MX173362B (es) 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US5461053A (en) * 1989-02-07 1995-10-24 Sanofi Pyridazine derivatives
PT93060B (pt) 1989-02-07 1995-12-29 Sanofi Sa Processo para a obtencao de derivados de piridazina e de composicoes farmaceuticas que os contem
GB9216298D0 (en) 1991-08-15 1992-09-16 Ici Plc Piperidine derivatives
EP0737189B1 (en) 1993-12-28 1999-07-28 PHARMACIA & UPJOHN COMPANY Heterocyclic compounds for the treatment of cns and cardiovascular disorders
DE4425145A1 (de) 1994-07-15 1996-01-18 Basf Ag Verwendung von Thiazol- und Thiadiazolverbindungen
TW406075B (en) 1994-12-13 2000-09-21 Upjohn Co Alkyl substituted piperidinyl and piperazinyl anti-AIDS compounds
US5560931A (en) * 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5753679A (en) 1995-05-10 1998-05-19 Hoffmann-La Roche Inc. Benzyl-piperidine derivatives
MY116093A (en) * 1996-02-26 2003-11-28 Upjohn Co Azolyl piperazinyl phenyl oxazolidinone antimicrobials
TW504510B (en) 1996-05-10 2002-10-01 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives
CN1265660A (zh) 1997-08-15 2000-09-06 辉瑞产品公司 2－(4－芳基或杂芳基－哌嗪－1－基甲基)－1h－吲哚衍生物
KR100261139B1 (ko) 1998-01-16 2000-08-01 황준수 신규한 알릴티오피리다진 유도체 및 그의 제조방법
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
DK1379520T3 (da) 2001-02-23 2006-08-21 Merck & Co Inc N-substituerede ikke-aryl-heterocykliske NMDA/NR2B-antagonister
CA2468529C (en) 2001-10-09 2011-03-01 Kyorin Pharmaceutical Co., Ltd. 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same
GB0127832D0 (en) 2001-11-20 2002-01-09 Jagotec Ag Method for the preparation of pharmaceutical nanosuspensions
US7812035B2 (en) 2001-12-11 2010-10-12 Sepracor Inc. 4-substituted piperidines, and methods of use thereof
CA2474322A1 (en) 2002-01-25 2003-07-31 Kylix Pharmaceuticals B.V. 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
EP1474401A2 (en) 2002-02-05 2004-11-10 Novo Nordisk A/S Novel aryl- and heteroarylpiperazines
JP4467307B2 (ja) 2002-02-22 2010-05-26 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー ５−ｈｔ受容体アンタゴニストとしてのピリジルスルホン誘導体
SE0201544D0 (sv) 2002-05-17 2002-05-17 Biovitrum Ab Novel compounds and thier use
WO2004028520A1 (ja) * 2002-09-26 2004-04-08 Mandom Corporation 防腐殺菌剤並びに該防腐殺菌剤を配合した化粧料、医薬品及び食品
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
AU2004224191A1 (en) 2003-03-24 2004-10-07 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
AU2003239845A1 (en) * 2003-05-07 2004-11-26 Ifac Gmbh And Co.Kg Compositions for the targetted release of fragrances and aromas
CN100582103C (zh) 2003-05-08 2010-01-20 杏林制药株式会社 作为搔痒治疗药有效的4-(2-呋喃甲酰基)氨基哌啶类化合物
CA2527093C (en) * 2003-06-04 2009-10-20 Merck & Co., Inc. 3-fluoro-piperidines as nmda/nr2b antagonists
WO2005005779A2 (en) 2003-07-14 2005-01-20 Genesis Mining Technologies (Pty) Ltd Dual retention cutting arrangement
BRPI0413048A (pt) 2003-07-29 2006-10-17 Novo Nordisk As composto, composição farmacêutica, uso de um composto, e, método para o tratamento de distúrbios ou doenças relacionados com o receptor h3 da histamina
ES2375134T3 (es) 2003-07-30 2012-02-27 Xenon Pharmaceuticals Inc. Derivados de piperazina y su uso como agentes terapéuticos.
WO2005013907A2 (en) 2003-08-07 2005-02-17 Japan Tobacco Inc. Pyrrolo[1,2-b]pyridazine derivatives
WO2005046581A2 (en) 2003-10-24 2005-05-26 Cheng Tao M D P18 in stem cell manipulations
BRPI0506676A (pt) 2004-02-10 2007-05-15 Janssen Phamaceutica N V piridazinona uréias como antagonistas de integrinas alfa4
CN1934092A (zh) 2004-03-23 2007-03-21 弗·哈夫曼-拉罗切有限公司 非核苷逆转录酶抑制剂
MXPA06012510A (es) 2004-04-28 2006-12-15 Pfizer Derivados de 3-heterociclil-4-fenil-triazol como inhibidores del receptor de vasopresina via.
CA2568524A1 (en) 2004-05-28 2005-12-15 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
KR20070057822A (ko) * 2004-08-09 2007-06-07 아스텔라스세이야쿠 가부시키가이샤 히스톤 디아세틸라제 (ｈｄａｃ) 억제제 활성을 갖는히드록시아미드 화합물
WO2006034440A2 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
WO2006055187A1 (en) 2004-10-29 2006-05-26 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as modulators of ppar
WO2006061376A1 (en) * 2004-12-08 2006-06-15 Solvay Pharmaceuticals B.V. Aryloxyethylamine derivatives with a combination of partial d0pamine-d2 receptor agonism and serotonin reuptake inhibition
US20100092505A1 (en) * 2005-04-05 2010-04-15 Elisabetta Bianchi Method for Shielding Functional Sites or Epitopes on Proteins
JP2008546784A (ja) 2005-06-20 2008-12-25 シェーリング コーポレイション ヒスタミンｈ３アンタゴニストとして有用なピペリジン誘導体
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
WO2007130383A2 (en) 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
JP2010500391A (ja) 2006-08-15 2010-01-07 エフ．ホフマン−ラ ロシュ アーゲー フェニル、ピリジン及びキノリン誘導体
CA2606658A1 (en) * 2006-10-13 2008-04-13 Mike Tyers Compositions and methods for treating neurological disorders or damage
JO2642B1 (en) * 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
TW200829566A (en) 2006-12-08 2008-07-16 Astrazeneca Ab Chemical compounds
JO2849B1 (en) * 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
EP2148872A1 (en) * 2007-04-23 2010-02-03 Janssen Pharmaceutica, N.V. Pyridine derivatives as fast dissociating dopamine 2 receptor antagonists
EP2148873B1 (en) * 2007-04-23 2012-08-29 Janssen Pharmaceutica, N.V. 4-alkoxypyridazine derivatives as fast dissociating dopamine 2 receptor antagonists
PE20091194A1 (es) * 2007-09-20 2009-09-05 Glaxo Group Ltd Derivados de heterociclicos como moduladores del receptor m1
WO2010000456A1 (en) * 2008-07-03 2010-01-07 Janssen Pharmaceutica Nv Substituted 6- (1-piperazinyl) -pyridazines as 5-ht6 receptor antagonists
JP5457450B2 (ja) * 2008-07-31 2014-04-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 迅速解離性ドーパミン２受容体拮抗薬としてのピペラジン−１−イル−トリフルオロメチル−置換−ピリジン

Also Published As

Publication number Publication date
EP2148879A1 (en) 2010-02-03
CL2008001158A1 (es) 2008-11-03
TWI423969B (zh) 2014-01-21
AU2008240729A1 (en) 2008-10-30
AR066242A1 (es) 2009-08-05
TW200911799A (en) 2009-03-16
IL201661A (en) 2015-07-30
CA2682671A1 (en) 2008-10-30
US8933101B2 (en) 2015-01-13
JP2010525015A (ja) 2010-07-22
KR20100016090A (ko) 2010-02-12
AU2008240729B2 (en) 2012-08-23
WO2008128996A1 (en) 2008-10-30
RU2009142981A (ru) 2011-05-27
JP5431306B2 (ja) 2014-03-05
US20100120860A1 (en) 2010-05-13
IL201661A0 (en) 2010-05-31
ES2400710T3 (es) 2013-04-11
CN101663299A (zh) 2010-03-03
RU2489431C2 (ru) 2013-08-10
CA2682671C (en) 2015-11-17
EP2148879B1 (en) 2012-11-28
KR101506156B1 (ko) 2015-03-26

Similar Documents

Publication Publication Date Title
HK1124317A1 (en) Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists
MX2009011416A (es) Tia(di)azoles como antagonistas del receptor de dopamina 2 de disociacion rapida.
TW200700391A (en) Pyridine-2-carboxamide derivatives as mglur5 antagonists
TW200833686A (en) Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors
JO2849B1 (en) Dopamine 2 receptor antagonists are rapidly hydrolyzed
SG179034A1 (en) 2 -aminodihydro [1, 3] thiazines as bace 2 inhibitors for the treatment of diabetes
IL189191A0 (en) Thiazolyl piperidine derivatives useful as h3 receptor modulators
NO20070336L (no) Indolderivater som histamin-reseptorantagonister
UA83862C2 (ru) Производные тиазола как модуляторы рецепторов канабиноидов
TN2009000180A1 (en) NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF
MX2009011415A (es) Derivados de 4-alcoxipiridazina como antagonistas del receptor de dopamina 2 de rapida disociacion.
NO20091590L (no) Heterocykliske amidforbindelser anvendbare som kinaseinhibitorer
ATE555099T1 (de) Dual wirkende benzimidazol-derivate und deren verwendung als blutdrucksenkende mittel
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
NO20064238L (no) Imidazolinderivater med CB1 agonistlsk aktivitet
DE602008001725D1 (de) 1-(1-benzylpiperidin-4-yl)benzimidazol-5-carbonsäurederivate zur behandlung von diabetes mellitus
MY148772A (en) Piperidinylamino-pyridazines and their use as fast dissociating dopamine 2 receptor antagonists
EA201170256A1 (ru) Пиперазин-1-илтрифторметилзамещенные пиридины в качестве быстро диссоциирующихся антагонистов d2 рецепторов дофамина
TW200509920A (en) Imidazole derivatives
UA83868C2 (ru) Производные бензимидазолона и хиназолинона в качестве агонистов человеческих рецепторов orl1
MY149973A (en) 3-carboxypropyl-aminotetralin derivatives as mu opioid receptor antagonists
MX2009011414A (es) Derivados de piridina como antagonistas del receptor de dopamina 2 de disociacion rapida.
MXPA05013233A (es) Derivados de imidazol heteroaril-substituidos como antagonistas del receptor de glutamato.
MY142085A (en) Imidazole derivatives
NO20090125L (no) Benzimidazolderivater som skal anvendes som antagonist for CB1-reseptor

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration